Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
about
Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patientsPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsNatural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patientsEfficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virusLiver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsPredicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapyDeciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsTest of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patientsVariation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis CDanoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsIFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansGenetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene.Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city.The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis CTwo IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.PharmGKB summary: peginterferon-α pathway.In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.HCV treatment in children and young adults with HIV/HCV co-infection in Europe.IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, IndiaInterleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision MakingIndividualization of chronic hepatitis C treatment according to the host characteristics.The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.A new standard of care for the treatment of chronic HCV infection.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Interferon combination therapy for HIV/hepatitis C virus coinfection.Host genomics and HCV treatment response.
P2860
Q26830804-6CB8A8A2-A87C-4E55-AEF7-96838BF490D6Q28740552-CDCD2EE8-CBC3-4F74-A1CB-0E12AF555B1BQ30365599-66FA5445-994F-42FA-AA31-49724D60C07FQ31115968-61534114-8D8D-4537-9C04-9AFDB358C9B5Q33423922-49EE1B9E-1019-4385-A738-C6047F611A7BQ33710740-50AB4BD9-F766-488A-9D33-46E08D91F6DCQ33737419-3237A095-6D31-453A-9F4D-5E9FC064785FQ33778756-D94A7D51-6E9D-46FE-A51B-4FCA2241A794Q33807010-056D2E34-5A8D-4292-96EA-75358BF65B02Q33889885-56DB04E6-BB81-4A72-8056-ADAE1D170E7FQ33948641-0930CA62-2830-4749-9E91-BCA6BBB97EE4Q34049322-09CDCF7F-FD18-47CB-8435-925E582879BFQ34157284-EC68CFB7-E3EE-458B-9005-9D230E8F59A5Q34429833-B62A19C8-25C3-499F-A03D-C6CA770B76D9Q34464613-6E8D204A-3AF9-4293-BC27-7CC36B22D9ECQ34473823-0888A8A4-89A9-4C83-8973-5B4352DBF8C6Q34796111-650EABEA-18F4-4B4A-AB37-D914F18112B9Q35027939-4B210DD2-8DA2-4FB0-97B3-C382279D6FA8Q35065912-B0392222-1E89-4AB1-B7BD-2650CD2B76E8Q35077010-6F869A82-1648-4056-BE2F-1B9140A8BD13Q35153222-4224CD74-C621-49C4-9A69-0D82D72B2793Q35238151-9BC3830A-14A4-4434-A45C-62DC005BFA05Q35959126-A5138065-9C4D-49E3-91D1-0E81E5F3BF20Q36008565-855E0074-923D-4029-AAA4-14699EB68D02Q36145087-7366FB3D-9A3E-4A7B-8CDC-D525BA78EC72Q36208380-1BF199F4-9588-441E-8D9E-6115CF3D8A81Q36224697-FFC90123-2B14-4321-B102-8A6A587EA252Q36590755-159E82EF-23DD-4247-9156-D25D8C9DEF3AQ37016495-6F88C5D2-16BC-4355-A15D-1A907C069F52Q37098372-C5C7B5A0-E408-4AF4-8DA6-EC76761535CDQ37428173-E9C9F04F-D43C-4C8C-8A0A-E2F793CCD201Q37613384-F04878B2-C978-43F9-ABA6-E0D52E642FF8Q37613481-CFA4249F-E833-4F88-A821-3254CA4B8D62Q37654502-07F0DDFF-C32B-4210-8D5E-6C49424F2F1FQ37809806-D641913D-8DA2-4492-B1FC-6A4DC8BE1A2CQ37862076-CF782C96-2303-4792-B230-06858F81F017Q37879701-EC1D317B-5AFF-450B-9E7E-7C441BA661EEQ37921307-D4C8A674-4506-4A57-9AA2-75B676B6EC96Q37931258-8016C843-9EB5-4400-84A7-61F0A6033BECQ37932036-120FFB84-BBAB-4019-84CB-8EB1532147AC
P2860
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@en
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@nl
type
label
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@en
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@nl
prefLabel
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@en
Prediction of response to pegy ...... ith HIV and hepatitis C virus.
@nl
P2093
P50
P356
P1476
Prediction of response to pegy ...... with HIV and hepatitis C virus
@en
P2093
Angela Camacho
Antonio Martínez
Carmen Roldán
Irene Salas
José A Mira
José C Palomares
Julián de la Torre
P304
P356
10.1086/656235
P407
P577
2010-10-01T00:00:00Z